Histone modifications in drug-resistant cancers: From a cancer stem cell and immune evasion perspective

참고문헌 (187)

1. Vasan, N., "A view on drug resistance in cancer", Nature, 575, pp.299~309 (2019)
2. Hanahan, D., "Hallmarks of cancer : new dimensions", Cancer Discov, 12, pp.31~46 (2022)
3. Sharma, P., "The future of immune checkpoint therapy", Science, 348, pp.56~61 (2015)
4. Kreso, A., "Evolution of the cancer stem cell model", Cell Stem Cell, 14, pp.275~291 (2014)
5. Saleh, R., "Acquired resistance to cancer immunotherapy : Role of tumor-mediated immunosuppression", Semin. Cancer Biol, 65, pp.13~27 (2020)
6. Sasidharan Nair, V., "DNA methylation and repressive H3K9 and H3K27trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer", Clin. Epigenet, 10, pp.78~ (2018)
7. D’Oto, A., "Histone demethylases and their roles in cancer epigenetics", J. Med. Oncol. Ther, 1, pp.34~40 (2016)
8. Bayik, D., "Cancer stem cell-immune cell crosstalk in tumour progression", Nat. Rev. Cancer, 21, pp.526~536 (2021)
9. Yang, Y., "Role of epigenetic regulation in plasticity of tumor immune microenvironment", Front. Immunol, 12, pp.640369~ (2021)
10. Valkenburg, K. C., "Wnt", β-catenin signaling in normal and cancer stem cells, 2011, pp.3, 2050~2079
11. Rheinbay, E., "An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma", Cell Rep, 3, pp.1567~1579 (2013)
12. Zheng, H., "PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas", Cancer Cell, 17, pp.497~509 (2010)
13. Cho, S., "Notch1 regulates the expression of the multidrug resistance gene ABCC1", MRP1 in cultured cancer cells, 2011, pp.108, 20778~20783
14. Wang, Z., "Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma", Cancer Res, 74, pp.6364~6374 (2014)
15. Jin, L., "STRAP promotes stemness of human colorectal cancer via epigenetic regulation of the NOTCH pathway", Cancer Res, 77, pp.5464~5478 (2017)
16. Ghoshal, P., "Loss of the SMRT", NCoR2 corepressor correlates with JAG2overexpression in multiple myeloma, 2009, pp.69, 4380~4387
17. Cochrane, C. R., "Hedgehog signaling in the maintenance of cancer stem cells", Cancers, 7, pp.1554~1585 (2015)
18. Canettieri, G., "Histone deacetylase and Cullin3-REN(KCTD11)ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation", Nat. Cell Biol, 12, pp.132~142 (2010)
19. To, K. K., "Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells", Mol. Cancer Res, 6, pp.151~164 (2008)
20. Jin, W., "Role of JAK", STAT3 signaling in the regulation of metastasis, the transition of cancer stem cells, and chemoresistance of cancer by epithelial–mesenchymal transition, 2020, pp.9, 217~
21. Yuan, Z. L., "Stat3 dimerization regulated by reversible acetylation of a single lysine residue", Science, 307, pp.269~273 (2005)
22. Xia, P., "PI3K", Akt, Am. J Cancer Res, pp.2015, 5[DOI]
23. Spangle, J. M., "The emerging role of PI3K", AKT-mediated epigenetic regulation in cancer, 2017, pp.1868, 123~131
24. Onder, T. T., "Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways", Cancer Res, 68, pp.3645~3654 (2008)
25. Toh, T. B., "Epigenetics in cancer stem cells", Mol. Cancer, 16, pp.29~ (2017)
26. Herranz, N., "Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor", Mol. Cell. Biol, 28, pp.4772~4781 (2008)
27. Shao, P., "Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis", Nucleic Acids Res, 45, pp.1687~1702 (2017)
28. Martinez-Gamero, C., "LSD1 : expanding functions in stem cells and differentiation", Cells, 10, pp.3252~ (2021)
29. Miller, S. A., "Lysine-specific demethylase 1 mediates AKT activity and promotes epithelial-to-mesenchymal transition in PIK3CA-mutant colorectal cancer", Mol. Cancer Res, 18, pp.264~277 (2020)
30. Zhang, H. S., "TSPAN8 promotes colorectal cancer cell growth and migration in LSD1-dependent manner", Life Sci, 241, pp.117114~ (2020)
31. Hsu, J. M., "STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion", Nat. Commun, 9, pp.1908~ (2018)
32. Meder, L., "Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer", Cancer Res, 78, pp.4270~4281 (2018)
33. Wang, Y., "Advancing to the era of cancer immunotherapy", Cancer Commun. (Lond), 41, pp.803~829 (2021)
34. Spranger, S., "Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy", Cancer Cell, 31, pp.711~723 (2017)
35. Tsuchiya, H., "Immune evasion by cancer stem cells", Regen. Ther, 17, pp.20~33 (2021)
36. Krempski, J., "Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer", J. Immunol, 186, pp.6905~6913 (2011)
37. Kawasaki, B. T., "Cancer stem cells, CD200 and immunoevasion", Trends Immunol, 29, pp.464~468 (2008)
38. Tan, Y., "Tumor-associated macrophages : a potential target for cancer therapy", Front. Oncol, 11, pp.693517~ (2021)
39. Dianat-Moghadam, H., "Immune evader cancer stem cells direct the perspective approaches to cancer immunotherapy", Stem Cell Res. Ther, 13, pp.150~ (2022)
40. Jinushi, M., "Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem", initiating cells, 2011, pp.108, 12425~12430
41. Fan, Q. M., "Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelialmesenchymal transition in hepatocellular carcinoma", Cancer Lett, 352, pp.160~168 (2014)
42. Lei, M. M. L., "Cancer stem cells: emerging key players in immune evasion of cancers", Front. Cell Dev. Biol, 9, pp.692940~ (2021)
43. Veglia, F., "Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity", Nat. Rev. Immunol, 21, pp.485~498 (2021)
44. Welte, T., "Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation", Nat. Cell Biol, 18, pp.632~644 (2016)
45. Ai, L., "Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation", Mol. Cancer, 18, pp.88~ (2019)
46. Lee, C. R., "Myeloid-derived suppressor cells are controlled by regulatory T cells via TGF-beta during murine colitis", Cell Rep, 17, pp.3219~3232 (2016)
47. Liu, S., "Regulatory T cells promote glioma cell stemness through TGF-beta-NF-kappaB-IL6-STAT3 signaling", Cancer Immunol. Immunother, 70, pp.2601~2616 (2021)
48. Xu, Y., "Sox2 communicates with Tregs through CCL1 to promote the stemness property of breast cancer cells", Stem Cells, 35, pp.2351~2365 (2017)
49. Rezalotfi, A., "Gastric cancer stem cells effect on Th17", Treg balance; a bench to beside perspective, 2019, pp.9, 226~
50. Oh, E., "Regulatory T cells induce metastasis by increasing Tgf-beta and enhancing the epithelial-mesenchymal transition", Cells, 8, pp.1387~ (2019)
51. Beck, B., "A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours", Nature, 478, pp.399~403 (2011)
52. Castriconi, R., "NK cells recognize and kill human glioblastoma cells with stem cell-like properties", J. Immunol, 182, pp.3530~3539 (2009)
53. Tallerico, R., "Human NK cells selective targeting of colon cancer-initiating cells : a role for natural cytotoxicity receptors and MHC class I molecules", J. Immunol, 190, pp.2381~2390 (2013)
54. Jewett, A., "Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell mediated lysis of cancer stem cells", Curr. Drug Deliv, 9, pp.5~16 (2012)
55. Akhter, M. Z., "Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM(+)CD45(+)phenotype", Oncogene, 37, pp.2089~2103 (2018)
56. Zhong, Y., "Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells", Cancer Lett, 299, pp.150~160 (2010)
57. Malladi, S., "Metastatic latency and immune evasion through autocrine inhibition of WNT", Cell, 165, pp.45~60 (2016)
58. Sainz, B. Jr., "ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells", Cancer Res, 74, pp.7309~7320 (2014)
59. Martin-Hijano, L., "The interactions between cancer stem cells and the innate interferon signaling pathway", Front. Immunol, 11, pp.526~ (2020)
60. Zhu, Y., "Influence of interferon-alpha on the expression of the cancer stem cell markers in pancreatic carcinoma cells", Exp. Cell Res, 324, pp.146~156 (2014)
61. Wilson, E. B., "Blockade of chronic type I interferon signaling to control persistent LCMV infection", Science, 340, pp.202~207 (2013)
62. Teijaro, J. R., "Persistent LCMV infection is controlled by blockade of type I interferon signaling", Science, 340, pp.207~211 (2013)
63. Musella, M., "Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B", Nat. Immunol, 23, pp.1379~1392 (2022)
64. Song, M., "Low-dose IFNgamma induces tumor cell stemness in tumor microenvironment of non-small cell lung cancer", Cancer Res, 79, pp.3737~3748 (2019)
65. Yang, L., "Histone H3K4 methyltransferases as targets for drug-resistant cancers", Biology, 10, pp.581~ (2021)
66. Muntean, A. G., "The pathogenesis of mixed-lineage leukemia", Annu. Rev. Pathol, 7, pp.283~301 (2012)
67. Krivtsov, A. V., "Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9", Nature, 442, pp.818~822 (2006)
68. Zeisig, B. B., "Reconstructing the disease model and epigenetic networks for MLL-AF4 leukemia", Cancer Cell, 14, pp.345~347 (2008)
69. Fiskus, W., "Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation(NPM1c)", Blood Cancer J, 12, pp.5~ (2022)
70. Malik, R., "Targeting the MLL complex in castration-resistant prostate cancer", Nat. Med, 21, pp.344~352 (2015)
71. Grinat, J., "The epigenetic regulator Mll1 is required for Wnt-driven intestinal tumorigenesis and cancer stemness", Nat. Commun, 11, pp.6422~ (2020)
72. Chen, R., "Kmt2c mutations enhance HSC self-renewal capacity and convey a selective advantage after chemotherapy", Cell Rep, 34, pp.108751~ (2021)
73. Wang, X., "Histone methyltransferase KMT2D cooperates with MEF2A to promote the stem-like properties of oral squamous cell carcinoma", Cell Biosci, 12, pp.49~ (2022)
74. Zhang, X., "MLL5(KMT2E) : structure, function, and clinical relevance", Cell. Mol. Life Sci, 74, pp.2333~2344 (2017)
75. Jin, M. L., "SETD1A-SOX2 axis is involved in tamoxifen resistance in estrogen receptor α-positive breast cancer cells", Theranostics, 12, pp.5761~5775 (2022)
76. Yang, L., "SETD1A promotes proliferation of castration-resistant prostate cancer cells via FOXM1 transcription", Cancers(Basel), 12, pp.1736~ (2020)
77. Wang, R., "An SETD1A", Wnt, J. Exp. Clin. Cancer Res, pp.2021, 40[DOI]
78. Zhang, H., "MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway", Stem Cells, 32, pp.2858~2868 (2014)
79. Hou, Z., "Blocking histone methyltransferase SETDB1 inhibits tumorigenesis and enhances cetuximab sensitivity in colorectal cancer", Cancer Lett, 487, pp.63~73 (2020)
80. Bergin, C. J., "G9a controls pluripotent-like identity and tumor-initiating function in human colorectal cancer", Oncogene, 40, pp.1191~1202 (2021)
81. Liu, S., "G9a is essential for EMT-mediated metastasis and maintenance of cancer stem cell-like characters in head and neck squamous cell carcinoma", Oncotarget, 6, pp.6887~6901 (2015)
82. Wang, L., "Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN", AKT signaling pathway, 2018, pp.9, 129~
83. Ciechomska, I. A., "BIX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cells", Sci. Rep, 6, pp.38723~ (2016)
84. Knutson, S. K., "Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2", Proc. Natl Acad. Sci. USA, 110, pp.7922~7927 (2013)
85. Fu, H., "Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF(V600E)by synergistically decreasing global trimethylation of H3K27", J. Cell. Mol. Med, 24, pp.3336~3345 (2020)
86. Adelaiye-Ogala, R., "EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming", Cancer Res, 77, pp.6651~6666 (2017)
87. Zhang, L., "Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer", Oncotarget, 5, pp.10665~10677 (2014)
88. Nassa, G., "Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells", Sci. Adv, 5, pp.eaav5590~ (2019)
89. Kurani, H., "DOT1L is a novel cancer stem cell target for triple-negative breast cancer", Clin. Cancer Res, 28, pp.1948~1965 (2022)
90. 황지원, "Protein arginine methyltransferases: promising targets for cancer therapy", Experimental and Molecular Medicine, 53, pp.1~21 (2021), 생화학분자생물학회[DOI]
91. Gao, Y., "The dual function of PRMT1 in modulating epithelial-mesenchymal transition and cellular senescence in breast cancer cells through regulation of ZEB1", Sci. Rep, 6, pp.19874~ (2016)
92. Katsuno, Y., "Arginine methylation of SMAD7 by PRMT1 in TGF-β-induced epithelial-mesenchymal transition and epithelial stem-cell generation", J. Biol. Chem, 293, pp.13059~13072 (2018)
93. Chiang, K., "PRMT5 is a critical regulator of breast cancer stem cell function via histone methylation and FOXP1 expression", Cell Rep, 21, pp.3498~3513 (2017)
94. Zheng, B. N., "Targeting PRMT5 activity inhibits the malignancy of hepatocellular carcinoma by promoting the transcription of HNF4α", Theranostics, 9, pp.2606~2617 (2019)
95. Wang, X., "Arginine methyltransferase PRMT5 methylates and stabilizes KLF5via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer", Cell Death Differ, 28, pp.2931~2945 (2021)
96. Sachamitr, P., "PRMT5 inhibition disrupts splicing and stemness in glioblastoma", Nat. Commun, 12, pp.979~ (2021)
97. Almeida-Rios, D., "Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer", Oncotarget, 7, pp.53018~53028 (2016)
98. Nakakido, M., "PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents", Oncotarget, 6, pp.30957~30967 (2015)
99. Huang, T., "PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells", Mol. Cell, 81, pp.1276~1291 (2021)
100. AlAbdi, L., "Oct4-mediated inhibition of Lsd1 activity promotes the active and primed state of pluripotency enhancers", Cell Rep, 30, pp.1478~1490 (2020)
101. Liu, C., "LSD1 stimulates cancer-associated fibroblasts to drive Notch3-dependent self-renewal of liver cancer stem-like cells", Cancer Res, 78, pp.938~949 (2018)
102. Yin, F., "LSD1 regulates pluripotency of embryonic stem", carcinoma cells through histone deacetylase 1-mediated deacetylation of histone H4 at lysine 16, 2014, pp.34, 158~179
103. Verigos, J., "The histone demethylase LSD1", ΚDM1A mediates chemoresistance in breast cancer via regulation of a stem cell program, 2019, pp.11, 1585~
104. Boulding, T., "LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer", Sci. Rep, 8, pp.73~ (2018)
105. Cuyàs, E., "The LSD1 inhibitor iadademstat(ORY-1001)targets SOX2-driven breast cancer stem cells : a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes", Aging, 12, pp.4794~4814 (2020)
106. Zhao, L. J., "Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness", EMBO Rep, 22, pp.e50922~ (2021)
107. Ramadoss, S., "Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance", Oncogene, 36, pp.6508~ (2017)
108. MacPherson, L., "HBO1 is required for the maintenance of leukaemia stem cells", Nature, 577, pp.266~270 (2020)
109. Di Martile, M., "Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells", Oncotarget, 7, pp.11332~11348 (2016)
110. Baell, J. B., "Inhibitors of histone acetyltransferases KAT6A", B induce senescence and arrest tumour growth, 2018, pp.560, 253~257
111. Yu, B., "KAT6A acetylation of SMAD3 regulates myeloid-derived suppressor cell recruitment, metastasis, and immunotherapy in triple-negative breast cancer", Adv. Sci, 8, pp.e2100014~ (2021)
112. Liu, W., "KAT6A, a novel regulator of beta-catenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1", Theranostics, 11, pp.6278~6292 (2021)
113. Simonsson, M., "The balance between acetylation and deacetylation controls Smad7 stability", J. Biol. Chem, 280, pp.21797~21803 (2005)
114. Chiu, C. C., "Grp78 as a therapeutic target for refractory head-neck cancer with CD24(-)CD44(+)stemness phenotype", Cancer Gene Ther, 20, pp.606~615 (2013)
115. Witt, A. E., "Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer", Oncogene, 36, pp.1707~1720 (2017)
116. Wu, M. Y., "MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer", Cancer Lett, 354, pp.311~319 (2014)
117. Yano, M., "Association of histone deacetylase expression with histology and prognosis of ovarian cancer", Oncol. Lett, 15, pp.3524~3531 (2018)
118. Marotta, L. L., "The JAK2", STAT3 signaling pathway is required for growth of CD44+CD24-stem cell-like breast cancer cells in human tumors, 2011, pp.121, 2723~2735
119. Gupta, M., "Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma : implications for therapy", Leukemia, 26, pp.1356~1364 (2012)
120. Bora-Singhal, N., "Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2", Sci. Rep, 10, pp.4722~ (2020)
121. Chen, X., "High levels of SIRT1 expression enhance tumorigenesis and associate with a poor prognosis of colorectal carcinoma patients", Sci. Rep, 4, pp.7481~ (2014)
122. Yi, J., "SIRT1 and p53, effect on cancer, senescence and beyond", Biochim. Biophys. Acta, 1804, pp.1684~1689 (2010)
123. Li, L., "Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib", Cancer Cell, 21, pp.266~281 (2012)
124. Kumar, B., "Suberoylanilide hydroxamic acid(SAHA)reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog", Genes Cancer, 6, pp.169~181 (2015)
125. Nalls, D., "Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells", PLoS ONE, 6, pp.e24099~ (2011)
126. Chen, P. L., "Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade", Cancer Discov, 6, pp.827~837 (2016)
127. Hugo, W., "Genomic and transcriptomic features of response to anti-PD-1therapy in metastatic melanoma", Cell, 168, pp.542~ (2017)
128. Haebe, J. R., "Emerging role of G9a in cancer stemness and promises as a therapeutic target", Oncogenesis, 10, pp.76~ (2021)
129. Lee, S., "Network inference analysis identifies SETDB1 as a key regulator for reverting colorectal cancer cells into differentiated normal-like cells", Mol. Cancer Res, 18, pp.118~129 (2020)
130. Segovia, C., "Inhibition of a G9a", DNMT network triggers immune-mediated bladder cancer regression, 2019, pp.25, 1073~1081
131. Seier, J. A., "Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma", J. Immunother. Cancer, 9, pp.e001335~ (2021)
132. Ishiguro, K., "Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis", Cell Death Discov, 7, pp.7~ (2021)
133. Griffin, G. K., "Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity", Nature, 595, pp.309~314 (2021)
134. Zhang, S. M., "KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements", Nature, 598, pp.682~687 (2021)
135. Zingg, D., "The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy", Cell Rep, 20, pp.854~867 (2017)
136. Wang, D., "Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity", Cell Rep, 23, pp.3262~3274 (2018)
137. Peng, D., "Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy", Nature, 527, pp.249~253 (2015)
138. Xiao, G., "EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma", J. Immunother. Cancer, 7, pp.300~ (2019)
139. Chen, S., "EZH2 promotes hepatocellular carcinoma progression through modulating miR-22", galectin-9 axis, 2018, pp.37, 3~
140. Goswami, S., "Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy", J. Clin. Invest, 128, pp.3813~3818 (2018)
141. Zheng, N. N., "Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression", World J. Gastroenterol, 26, pp.3737~3749 (2020)
142. Hu, R., "PRMT5 inhibition promotes PD-L1 expression and immunoresistance in lung cancer", Front. Immunol, 12, pp.722188~ (2021)
143. Verigos, J., "The histone demethylase LSD1", KappaDM1A mediates chemoresistance in breast cancer via regulation of a stem cell program, 2019, pp.11, 1585~
144. Sheng, W., "LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade", Cell, 174, pp.549~563 (2018)
145. Qin, Y., "Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade", Oncogene, 38, pp.390~405 (2019)
146. Huang, M., "Targeting KDM1A attenuates Wnt", beta-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma, 2017, pp.398, 12~21
147. Sheng, W., "Simultaneous inhibition of LSD1 and TGFbeta enables eradication of poorly immunogenic tumors with anti-PD-1 treatment", Cancer Discov, 11, pp.1970~1981 (2021)
148. Xu, S., "LSD1 silencing contributes to enhanced efficacy of anti-CD47", PD-L1immunotherapy in cervical cancer, 2021, pp.12, 282~
149. Han, Y., "Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade", Cell Death Dis, 12, pp.993~ (2021)
150. Hogg, S. J., "Targeting the epigenetic regulation of antitumour immunity", Nat. Rev. Drug Discov, 19, pp.776~800 (2020)
151. Khan, A. N., "Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells", Cancer Immunol. Immunother, 57, pp.647~654 (2008)
152. Zheng, H., "HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma", Clin. Cancer Res, 22, pp.4119~4132 (2016)
153. Woods, D. M., "The antimelanoma activity of the histone deacetylase inhibitor panobinostat(LBH589)is mediated by direct tumor cytotoxicity and increased tumor immunogenicity", Melanoma Res, 23, pp.341~348 (2013)
154. Woods, D. M., "HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade", Cancer Immunol. Res, 3, pp.1375~1385 (2015)
155. Oki, Y., "Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1expression", Blood Cancer J, 4, pp.e236~ (2014)
156. Terranova-Barberio, M., "HDAC inhibition potentiates immunotherapy in triple negative breast cancer", Oncotarget, 8, pp.114156~114172 (2017)
157. Briere, D., "The class I", IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy, 2018, pp.67, 381~392
158. Topper, M. J., "Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer", Cell, 171, pp.1284~1300 (2017)
159. Kim, K., "Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells", Proc. Natl Acad. Sci. USA, 111, pp.11774~11779 (2014)
160. Orillion, A., "Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma", Clin Cancer Res, 23, pp.5187~5201 (2017)
161. Truong, A. S., "Entinostat induces antitumor immune responses through immune editing of tumor neoantigens", J. Clin. Invest, 131, pp.e138560~ (2021)
162. Knox, T., "Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells", Sci. Rep, 9, pp.6136~ (2019)
163. Bae, J., "Histone deacetylase(HDAC)inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors", Leukemia, 32, pp.1932~1947 (2018)
164. Wong, D. J., "Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function", Cancer Immunol. Res, 2, pp.459~468 (2014)
165. Kroesen, M., "HDAC inhibitors and immunotherapy; a double edged sword?", Oncotarget, 5, pp.6558~6572 (2014)
166. Fan, P., "Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer", J. Exp. Clin. Cancer Res, 38, pp.47~ (2019)
167. Gounder, M., "Tazemetostat in advanced epithelioid sarcoma with loss of INI1", SMARCB1 : an international, open-label, phase 2 basket study, 2020, pp.21, 1423~1432
168. Izutsu, K., "An open-label, single-arm, phase 2 trial of valemetostat in relapsed or refractory adult T-cell leukemia", lymphoma, 2022, pp.141, 1159~1168
169. Xue, K., "Vorinostat, a histone deacetylase(HDAC)inhibitor, promotes cell cycle arrest and re-sensitizes rituximab-and chemo-resistant lymphoma cells to chemotherapy agents", J. Cancer Res. Clin. Oncol, 142, pp.379~387 (2016)
170. Nakajima, W., "Combination with vorinostat overcomes ABT-263(navitoclax)resistance of small cell lung cancer", Cancer Biol. Ther, 17, pp.27~35 (2016)
171. enhances the efficacy of an anti-PD-1 antibody, "Cancer Biol. Ther", 2019, 109~121
172. Piro, G., "Vorinostat potentiates 5-fluorouracil", cisplatin combination by inhibiting chemotherapy-induced EGFR nuclear translocation and increasing cisplatin uptake, 2019, pp.18, 1405~1417
173. Lin, C. Y., "Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer", Cancer Lett, 508, pp.76~91 (2021)
174. Park, S. E., "Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer", Invest. New Drugs, 36, pp.195~205 (2018)
175. To, K. K., "Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat", Lung Cancer, 103, pp.58~65 (2017)
176. Llopiz, D., "Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model", Cancer Immunol. Immunother, 68, pp.379~393 (2019)
177. Savickiene, J., "Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells", Anticancer Drugs, 25, pp.938~949 (2014)
178. Mondello, P., "Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations", JCI Insight, 3, pp.e125568~ (2018)
179. Jiang, X. J., "Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-kappaB pathways", Cancer Lett, 326, pp.135~142 (2012)
180. Tate, C. R., "Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat", Breast Cancer Res, 14, pp.R79~ (2012)
181. Shahbazi, J., "The bromodomain inhibitor JQ1 and the histone deacetylase inhibitor panobinostat synergistically reduce N-Myc expression and induce anticancer effects", Clin. Cancer Res, 22, pp.2534~2544 (2016)
182. Medon, M., "HDAC inhibitor panobinostat engages host innate immune defenses to promote the tumoricidal effects of trastuzumab in HER2(+)tumors", Cancer Res, 77, pp.2594~2606 (2017)
183. Lee, W. Y., "Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ", Int. J. Cancer, 141, pp.1921~1931 (2017)
184. Ferrari, A. C., "Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer", Clin. Cancer Res, 25, pp.52~63 (2019)
185. Zang, H., "Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat(LBH589)", Cancer, 126, pp.2024~2033 (2020)
186. Wanitpongpun, C., "Tamoxifen enhances romidepsin-induced apoptosis in T-cell malignant cells via activation of FOXO1 signaling pathway", Leukemia Lymphoma, 62, pp.1585~1596 (2021)
187. Cooper, S. J., "Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers", Mol. Cancer Ther, 11, pp.2105~2115 (2012)

관련 논문AI추천